Login:
 
Does long-term 5-ARI use increase risk of prostate cancer? Practitioner 2013; 257 (1763):7-11

Does long-term 5-ARI use increase risk of prostate cancer?

25 Jul 2013Pais-up subscribers

Treatment for four years with a 5-alpha reductase inhibitor (5-ARI) for lower urinary tract symptoms (LUTS) secondary to benign prostatic enlargement was not associated with the development of prostate cancer, a case control study has found.

Paid-up subscribersThis article can be accessed only if you are a paid-up subscriber to The Practitioner.

To view current online and print subscription rates, and to contact the subscription department, click Subscribe today .